About OrthoLogic Mission Vision Company History Research & Development Investors Safe Harbor Statement
May 8, 2008 - OrthoLogic Announces Positive Safety Data for Initial AZX100 Phase 1 Human Clinical Trial in Dermal/Hypertrophic Scarring
May 7, 2008 - OrthoLogic Announces First Quarter 2008 Financial Results and Conference Call
Mar 5, 2008 - OrthoLogic Announces Year End 2007 Operating Results and Stock Repurchase Program
Feb 29, 2008 - OrthoLogic Announces Initiation of Dosing for AZX100 Phase 1 Human Clinical Trial in Dermal/Hypertrophic Scarring
- Past Press Releases
Thrombin peptide Chrysalin® stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study
Phase 3 Acceleration of Distal Radius Fracture Healing with a Thrombin Receptor Binding Peptide
Contact OrthoLogic
